ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB) Stock Pass Above Fifty Day Moving Average – What’s Next?

ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB)’s share price crossed above its fifty day moving average during trading on Monday . The stock has a fifty day moving average of $88.19 and traded as high as $102.28. ProShares Ultra Nasdaq Biotechnology shares last traded at $99.86, with a volume of 16,137 shares traded.

ProShares Ultra Nasdaq Biotechnology Price Performance

The firm has a market capitalization of $83.88 million, a PE ratio of 20.68 and a beta of 1.19. The firm has a fifty day moving average price of $88.19 and a 200 day moving average price of $84.84.

Institutional Trading of ProShares Ultra Nasdaq Biotechnology

Several institutional investors and hedge funds have recently bought and sold shares of BIB. Kaizen Financial Strategies lifted its stake in ProShares Ultra Nasdaq Biotechnology by 4.7% during the first quarter. Kaizen Financial Strategies now owns 5,565 shares of the exchange traded fund’s stock valued at $483,000 after buying an additional 250 shares in the last quarter. Franklin Resources Inc. acquired a new position in shares of ProShares Ultra Nasdaq Biotechnology in the second quarter worth about $32,000. Finally, Citadel Advisors LLC purchased a new position in shares of ProShares Ultra Nasdaq Biotechnology in the third quarter worth approximately $307,000.

ProShares Ultra Nasdaq Biotechnology Company Profile

ProShares Ultra Nasdaq Biotechnology (the Fund) seeks daily investment results, before fees and expenses, that correspond to twice (200%) the daily performance of the Index. The return of the Fund for a period longer than a single trading day will be the result of each day’s returns compounded over the period, which will very likely differ from the inverse of the return of the Dow Jones United States Basic Materials Index (the Index) for that period. The Fund does not seek to achieve its stated investment objective over a period of time greater than one day.